Fresenius Medical Care AG has announced a significant leadership change with the appointment of Shervin J. Korangy as the new Chief Executive Officer (CEO) and Chair of the Management Board, effective October 12, 2026. Korangy succeeds Helen Giza, who has led the company for four years, marking a pivotal moment in the company's strategic direction.
This transition comes as Fresenius Medical Care, a leading provider of products and services for individuals with renal diseases, aims to accelerate its long-term profitable growth. The company has laid a strong foundation under Giza's leadership, optimizing its portfolio and implementing the FME25+ transformation program, which has streamlined operations and reduced costs significantly.
According to the recent SEC filing (accession number 0001104659-26-114302), Korangy brings extensive leadership experience in healthcare and life sciences. His previous role as CEO of BVI Medical saw him transform the company into a global leader in surgical eye care. Having served on Fresenius Medical Care's Supervisory Board since 2023, Korangy is well-acquainted with the company's strategic context and opportunities in the dialysis market.
Fresenius Medical Care operates within the SIC description of Services-Misc Health & Allied Services, NEC, and this leadership change may influence the broader healthcare industry, particularly in renal care. The company aims to build on its existing strengths to enhance innovation and market leadership while delivering sustainable value to patients and shareholders.
In a statement, Michael Sen, Chairman of the Supervisory Board, expressed gratitude for Giza's leadership, noting the company's improved efficiency and profitability during her tenure. Korangy emphasized his commitment to accelerating innovation and improving patient outcomes, stating, "I am confident about what FME can achieve. I look forward to working with the leadership team to deliver against elevated ambitions and provide our patients with the optimal level of care."
The filing does not specify what the next steps will be following this leadership transition, but it indicates a clear intention to continue enhancing the company's market position and operational effectiveness.